Note 11 - Income Loss Per Share

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 11—Income Loss per Share

Basic and diluted loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted weighted average shares outstanding for the period ended March 31, 2014 and March 31, 2013 and the cumulative period from Inception to March 31, 2014 excludes all shares underlying stock options and warrants, since the effects would be anti-dilutive. Accordingly, basic and diluted loss per share is the same. 

Due to the Merger on August 25, 2013, the earnings per share for the period before the acquisition date presented in these financial statements were computed based on Immune Ltd.’s historical weighted-average number of shares outstanding, multiplied by the exchange ratio that was established in the Merger. Therefore, unless otherwise noted, all share and per-share amounts for all periods presented have been retroactively adjusted to give the effect to the exchange ratio. Such excluded the potentially dilutive shares as follows:

	Three month period ended March 31,
	2014		2013
Common stock options		4,422,573		2,470,217
Unvested stock awards		300,000		—
Common shares issuable upon conversion of Preferred C Stock		3,141,176		—
Warrants		5,490,018		730,554
Total potentially dilutive shares excluded from calculation		13,353,767		3,200,771